RecruitingNot ApplicableNCT07583823

Elevated Rate Pacing of Cardiac Amyloidosis

Sponsor

University of Minnesota

Enrollment

10 participants

Start Date

Oct 10, 2025

Study Type

INTERVENTIONAL

Conditions

Cardiac Amyloidosis Pacemaker

Summary

This study aims to better quantify the improvements in heart failure symptoms and exercise tolerance before and after the heart rate elevation in a cohort of 10 cardiac amyloidosis patients with preexisting pacemakers.

Eligibility

Min Age: 18 Years

Inclusion Criteria7

Adults 18 and older
Diagnosis of cardiac amyloidosis as indicated by the criteria set forth in guidelines such as in Kittleson et al: "2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee
Implanted Cardiac Pacemaker (+/- Defibrillator)
Pacemaker mode of AAI or DDD if in sinus rhythm, VVI acceptable if permanent atrial fibrillation
Non-dilated left ventricle by echocardiography
Ability to provide written consent
English Speaking

Exclusion Criteria2

Paced QRS duration of >150 ms (indicator for pacing mediated dyssynchrony)
Dilated left ventricle

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERPacemaker Rate

CA clinic patients with pacemakers will receive a personalized pacing protocol individual to their height and left ventricular ejection fraction.

Locations(1)

University of Minnesota

Minneapolis, Minnesota, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07583823

Related Trials

[64Cu]FBP8 PET for Early Detection of Intracardiac Thrombus in Amyloid Cardiomyopathy

NCT075603061 location

Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis

NCT060344056 locations